• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Teva Pharmaceutical Industries

Teva Pharmaceutical Industries

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Research
  1. Teva Receives CHMP Positive Opinion for Seasonique® Extended-Regimen Contraceptive for Marketing Authorization in Several European Countries

    Teva Receives CHMP Positive Opinion for Seasonique® Extended-Regimen Contraceptive for Marketing Authorization in Several European Countries

  2. OncoGenex Announces Cedar™ Clinical Trial Evaluating Apatorsen in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer is Now Open for Enrollment

    OncoGenex Announces Cedar™ Clinical Trial Evaluating Apatorsen in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer is Now Open for Enrollment

  3. Research and Markets: PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market

    Research and Markets: PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market

  4. BioLight Announces Issuance of U.S. Patent for the Long-Term Controlled-Release Drug-Delivery Insert Platform

    BioLight Announces Issuance of U.S. Patent for the Long-Term Controlled-Release Drug-Delivery Insert Platform

  5. QRxPharma Announces Board Resignations

    QRxPharma Announces Board Resignations

  6. Our Outlook for the Credit Markets

    Widening investment-grade credit spreads and rising interest rates lead to losses.

  7. Credit Market Outlook: Tight Spreads Will Keep a Lid on Returns

    As credit spreads have tightened on a nearly continuous trend over the past year, they are becoming richly valued relative to their historical average.

  8. Credit Market Outlook: Bonds Priced for the Benign

    Corporate credit spreads are fairly valued--albeit at the tight end of the range that we view as fairly valued.

1234
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.